Skip to content
MARKETS / NASDAQ / CTMX
NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP

CytomX Therapeutics, Inc. CTMX

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$76.2M
▼ 44.8% YoY
$-17.4M
▼ 154.5% YoY
$-75.8M
In brief

What this company does

Our most advanced clinical-stage program is Varseta-M, an investigational, conditionally activated antibody-drug conjugate (“ADC”) targeting epithelial cell adhesion molecule (“EpCAM”). As of December 31, 2025, we had 69 full-time employees. Our operations commenced in February 2008 when our predecessor entity was formed. We were incorporated in Delaware in September 2010. We maintain our executive offices at 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080, and our main telephone number is (650) 515-3185. We view our operations and measure our business as one reportable segment operating in the United States.

Written from the business description in CytomX Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 16 March 2026. Every sentence was checked against that document before publication.

Growth
USD 76.2M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 76.2 · Net income -17.4
50M100M-50M-100M2013201520172019202120232025
Compound annual growth
+12.8%
+2.2%
+25.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−23 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -29.3% · Net -22.8%
-500%-1000%-1500%2013201520172019202120232025
ROE
FY2025 · ROE -35.2%
-200%-400%-600%2013201520172019202120232025

Each USD of equity lost 35 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -75.8
80M160M-50M-100M2013201520172019202120232025

Total assetsUSD 151.6M
EquityUSD 99.0M
CashUSD 12.7M
Current ratio3.09×

Equity funds 65% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.10.10.10.10.00.10.00.10.10.00.00.00.0
Operating income $B−0.00.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.0−0.0−0.0
EBITDA $B−0.00.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.0··
Income tax $B0.00.00.00.00.0−0.0−0.00.0−0.0−0.00.00.00.0
Net income $B−0.00.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.10.0−0.1−0.10.2−0.0−0.00.0−0.0
EPS, diluted $········−1.16−1.63−4.90−35.25−24.46
Dividend / sh $·············
Payout %·············
ROE %−35.2····−732.6−164.7−82.3−58.1−57.6−148.9··
Shares out B0.170.080.070.070.070.050.050.050.040.040.040.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 42 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 34 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2013

Share this section

Download image